Sab Biotherapeutics Stock Book Value Per Share

SABSW Stock

USD 0.07 0.0008 1.17%

SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.

	Last Reported	Projected for Next Year
Book Value Per Share	10.38	7.50
Tangible Book Value Per Share	10.38	7.50

Book Value Per Share is likely to drop to 7.50 in 2024. Tangible Book Value Per Share is likely to drop to 7.50 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SAB Biotherapeutics Company Book Value Per Share Analysis

SAB Biotherapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current SAB Biotherapeutics Book Value Per Share

4.00 X

Most of SAB Biotherapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

SAB Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Book Value Per Share. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue
Total Assets		0.98	-0.87	-0.56	0.26	0.92	0.26	0.69	0.98	-0.86	0.99	-0.65	0.86	0.07	-0.38	0.64
Total Stockholder Equity	0.98		-0.85	-0.57	0.3	0.9	0.32	0.54	1.0	-0.81	0.96	-0.64	0.86	0.17	-0.4	0.65
Net Debt	-0.87	-0.85		0.86	0.2	-0.91	0.16	-0.64	-0.85	0.61	-0.89	0.94	-0.96	-0.39	0.72	-0.91
Retained Earnings	-0.56	-0.57	0.86		0.59	-0.74	0.54	-0.31	-0.58	0.18	-0.59	0.95	-0.78	-0.75	0.79	-0.94
Accounts Payable	0.26	0.3	0.2	0.59		0.0	0.98	0.01	0.3	-0.56	0.2	0.49	-0.06	-0.66	0.5	-0.43
Long Term Debt	0.92	0.9	-0.91	-0.74	0.0		-0.02	0.65	0.9	-0.76	0.87	-0.75	0.83	0.22	-0.4	0.72
Net Receivables	0.26	0.32	0.16	0.54	0.98	-0.02		-0.06	0.32	-0.51	0.22	0.42	0.01	-0.58	0.37	-0.34
Total Liab	0.69	0.54	-0.64	-0.31	0.01	0.65	-0.06		0.53	-0.72	0.69	-0.46	0.53	-0.29	-0.16	0.34
Net Invested Capital	0.98	1.0	-0.85	-0.58	0.3	0.9	0.32	0.53		-0.8	0.96	-0.64	0.86	0.18	-0.4	0.66
Short Long Term Debt	-0.86	-0.81	0.61	0.18	-0.56	-0.76	-0.51	-0.72	-0.8		-0.79	0.31	-0.62	0.42	0.02	-0.28
Total Current Assets	0.99	0.96	-0.89	-0.59	0.2	0.87	0.22	0.69	0.96	-0.79		-0.7	0.89	0.14	-0.48	0.69
Capital Stock	-0.65	-0.64	0.94	0.95	0.49	-0.75	0.42	-0.46	-0.64	0.31	-0.7		-0.9	-0.61	0.89	-0.99
Net Working Capital	0.86	0.86	-0.96	-0.78	-0.06	0.83	0.01	0.53	0.86	-0.62	0.89	-0.9		0.35	-0.78	0.91
Short Term Debt	0.07	0.17	-0.39	-0.75	-0.66	0.22	-0.58	-0.29	0.18	0.42	0.14	-0.61	0.35		-0.66	0.65
Common Stock	-0.38	-0.4	0.72	0.79	0.5	-0.4	0.37	-0.16	-0.4	0.02	-0.48	0.89	-0.78	-0.66		-0.91
Current Deferred Revenue	0.64	0.65	-0.91	-0.94	-0.43	0.72	-0.34	0.34	0.66	-0.28	0.69	-0.99	0.91	0.65	-0.91

Click cells to compare fundamentals

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict SAB Biotherapeutics

Book Value Per Share Over Time

SAB Common Stock Shares Outstanding

Common Stock Shares Outstanding

9.41 Million

At this time, SAB Biotherapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, the book value per share of SAB Biotherapeutics is about 3.998 times. This is 335.18% lower than that of the Biotechnology sector and 101.61% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.79% higher than that of the company.

SAB Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.

SAB Biotherapeutics is currently under evaluation in book value per share category among its peers.

SAB Fundamentals

	Return On Equity	-1.75
	Return On Asset	-0.79
	Operating Margin	(34.23) %
	Number Of Shares Shorted	2.51 K
	Price To Earning	0.21 X
	Revenue	2.24 M
	EBITDA	(38.08 M)
	Net Income	(42.19 M)
	Total Debt	5.91 M
	Book Value Per Share	4.00 X
	Cash Flow From Operations	(25.12 M)
	Earnings Per Share	0.29 X
	Number Of Employees	57
	Beta	0.64
	Total Asset	83.94 M
	Retained Earnings	(90.06 M)
	Working Capital	48.09 M
	Net Asset	83.94 M

About SAB Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC